丁艳芳 - 大连医科大学

个人简介

丁艳芳，硕士，副教授，硕士生导师。2000年毕业于大连医科大学妇产科学专业,获学士学位,2003年获大连医科大学人体解剖与组织胚胎学专业硕士学位。自毕业以来，一直在大连医科大学组织胚胎学教研室任教。主持国家自然科学基金一项，大连市科技项目一项，作为主要参与者参加科技部国际合作项目、国家自然科学基金及省市级项目十余项。以第一作者和通讯作者的身份发表SCI论文和核心期刊论文十余篇。作为主要成员获得辽宁省科学技术三等奖一项，获授权发明专利2项。主要承担留学生及本科教学，积极参与教育改革，参与编写人卫、科学及清华大学出版社规划教材及专著5部。

研究领域

（1）miRNA 在肾小球发育及疾病中的基因表达与调控；（2）miRNA在卵巢癌原发性耐药中的基因表达与调控。

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

[1] Zhang X ,Guo G ,Wang G,Zhao J,Wang B,Yu X ,Ding Y,Profile of differentially expressed miRNAs in high-grade serous carcinoma and clear cell ovarian carcinoma, and the expression of miR-510 in ovarian carcinoma，Molecular Medicine Reports (IF=1.559)，2015,12(6)：8021-8031.(通讯作者) [2] Zhao H, Ding Y,Tie B,Sun ZF,Jiang JY,Zhao J,Lin X,Cui S.miRNA expression pattern associated with prognosis in elderly patients with advanced OPSC and OCC，International Journal of Oncology(IF=3.018),2013,43(3)：839-849.(并列第一作者) [3] Ding YF,Wang G.,Zhao J, Wu X,Cui M,Li T, Li Y, Cui S.The role of miR-200c in ovarian cancer patients with paclitaxel resistance. International Journal of Gynecological Cancer.(IF=2.116),2016,26(suppl 3):672-672 [4] DingY, Zhang X, Cui S.Role of miR-206 in cisplatin resistance of ovarian serous carcinoma.International Journal of Gynecological Cancer (IF=1.958) 2014, 24 (9) : 88-88 [5] Zhao HN,Yu XT,Ding YF,Zhao JY,Wang G ,Wu X,Jiang JY ,Peng C ,Guo GZ, Cui SY.MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2, ONCOTARGET (IF = 5), 7( 33): 53254-53268 [6] Wang YT, Wang CY , Zhao J,Ding YF, Li L .A cost-effective method to prepare curcumin nanosuspensions with enhanced oral bioavailabilityJOURNAL OF COLLOID AND INTERFACE SCIENCE(IF=3.782)，485 : 91-98 [7] Xu YW ,Wang CY ,Ding YF , Wang YT,Liu KX ,Tian Y ,Gao M, Li Z ,Zhang JB,Li, L .Nanoparticles with Optimal Ratiometric Co-Delivery of Docetaxel with Gambogic Acid for Treatment of Multidrug-Resistant Breast Cancer. JOURNAL OF BIOMEDICAL NANOTECHNOLOGY(IF=3.929),201612(9) :1774-1781 [8] Zhao H,Liu S,Wang G,Wu X,Ding Y,Guo G,Jiang J ,Cui S .Expression of miR-136 is associated with the primary cisplatin resistance of human epithelial ovarian cancer, Oncology Reports(IF=2.6),2014,33(2)：591-598. [9] Yu X,Zhang X ,Bi T，Ding Y, Zhao J,Wang C,Jia T,Han D,Guo G，Wang B，Jiang J,Cui S，MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma，Tumor Biology(IF=2.5),2013,34（6）：3501-3508. [10] Zhao JY,Liu CQ,Zhao H,Ding YF,Bi T,Wang B,Lin XC,Guo G, Cui SY. Synchronous detection of miRNAs, their targets and downstream proteins in transferred FFPE sections: Applications in clinical and basic research，Methods(IF=3.7)，2012,58(2)：156-163